Ivabradine Teva

Active Ingredient:: Ivabradine
Origin:: EU

Ivabradine Teva (Ivabradine)

Q: What conditions is Ivabradine Teva used for?

Ivabradine Teva is indicated for the symptomatic treatment of chronic stable angina and for reducing hospitalization risk in patients with heart failure with reduced ejection fraction. It works by lowering heart rate without affecting myocardial contractility, helping to balance oxygen supply and demand in the heart.

Q: How does ivabradine work to lower heart rate?

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the primary pacemaker of the heart. By inhibiting this current, the drug slows the spontaneous depolarisation of pacemaker cells, resulting in a lower resting heart rate while preserving contractile strength and blood pressure.

Q: What is the usual dose of Ivabradine Teva?

The exact dose of Ivabradine Teva is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate target, and tolerance. Dosage adjustments may be needed for renal or hepatic impairment, and the prescriber will provide individualized instructions.

Q: Is Ivabradine safe during pregnancy or breastfeeding?

Safety data for ivabradine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

Q: How do I order Ivabradine Teva from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does ivabradine compare with beta‑blockers?

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting beta‑adrenergic receptors, blood pressure, or contractility. This makes it useful when beta‑blockers are contraindicated, not tolerated, or insufficient for heart‑rate control.

Q: What are the storage requirements for Ivabradine Teva?

Ivabradine Teva tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Q: How is Ivabradine Teva administered?

Ivabradine Teva is taken orally, usually with a glass of water. It is commonly prescribed to be taken with meals to improve absorption, but the exact timing and frequency should follow the prescriber’s instructions.

Q: What are the most serious risks associated with ivabradine?

The most serious risks include symptomatic bradycardia, atrial fibrillation, high‑grade atrioventricular block, severe hypotension, and persistent visual disturbances. Patients should be monitored for these events, especially when starting therapy or adjusting the dose.

Q: Who should not use Ivabradine Teva?

Ivabradine is contraindicated in patients with severe sinus bradycardia (resting heart rate <50 bpm), acute decompensated heart failure, sick sinus syndrome, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine.

Ivabradine, the active ingredient in Ivabradine Teva, is a If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate and is employed in the management of chronic stable angina and heart failure in adults.

GNH India supplies Ivabradine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Teva B.V

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine acts on the cardiac If current to control heart rate in conditions where reduced myocardial oxygen demand is beneficial.
Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate without affecting contractility.
Heart failure with reduced ejection fraction: improves symptoms and may decrease hospitalisations by maintaining a lower resting heart rate.
Sinus rhythm tachycardia: provides heart‑rate control when beta‑blockers are contraindicated or insufficient.

How It Works

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, which slows depolarisation of pacemaker cells. This results in a reduction of spontaneous heart‑rate firing while preserving myocardial contractility and ventricular conduction, thereby decreasing cardiac oxygen consumption without altering blood pressure.

Side Effects

Ivabradine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

Bradycardia: heart rate falls below the intended therapeutic range.
Visual disturbances (phosphenes): transient luminous phenomena, especially in low‑light conditions.
Headache: mild to moderate intensity.
Dizziness or vertigo.
Fatigue or general weakness.
Blurred vision.

Serious or Rare Side Effects

Symptomatic bradycardia requiring medical intervention.
Atrial fibrillation or other supraventricular arrhythmias.
Severe hypotension.
High‑grade atrioventricular block.
Persistent visual impairment.
Severe allergic reactions such as rash, angioedema, or anaphylaxis.

Precautions & Warnings

Before initiating therapy, clinicians should assess cardiac status and concomitant medications.

Severe bradycardia: avoid use in patients with resting heart rate <50 bpm.
Concomitant beta‑blockers or calcium‑channel blockers: monitor for excessive heart‑rate reduction.
Strong CYP3A4 inhibitors: dose adjustment or avoidance may be required.
Hepatic impairment: consider reduced dosing in moderate to severe liver disease.
Pregnancy and lactation: safety not established; use only if potential benefit justifies risk.
Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Ivabradine may interact with several drug classes, necessitating careful review.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): markedly increase ivabradine exposure.
Other heart‑rate lowering agents (beta‑blockers, digoxin, diltiazem): risk of profound bradycardia.
Concomitant drugs that cause QT prolongation: may exacerbate arrhythmic risk.

Moderate Interactions (Monitor Closely)

Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise plasma levels.
CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.
Antihypertensives: monitor blood pressure and heart rate for additive effects.

Frequently Asked Questions

Ivabradine Teva is indicated for the symptomatic treatment of chronic stable angina and for reducing hospitalization risk in patients with heart failure with reduced ejection fraction. It works by lowering heart rate without affecting myocardial contractility, helping to balance oxygen supply and demand in the heart.

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the primary pacemaker of the heart. By inhibiting this current, the drug slows the spontaneous depolarisation of pacemaker cells, resulting in a lower resting heart rate while preserving contractile strength and blood pressure.

The exact dose of Ivabradine Teva is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate target, and tolerance. Dosage adjustments may be needed for renal or hepatic impairment, and the prescriber will provide individualized instructions.

Safety data for ivabradine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting beta‑adrenergic receptors, blood pressure, or contractility. This makes it useful when beta‑blockers are contraindicated, not tolerated, or insufficient for heart‑rate control.

Ivabradine Teva tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Ivabradine Teva is taken orally, usually with a glass of water. It is commonly prescribed to be taken with meals to improve absorption, but the exact timing and frequency should follow the prescriber’s instructions.

The most serious risks include symptomatic bradycardia, atrial fibrillation, high‑grade atrioventricular block, severe hypotension, and persistent visual disturbances. Patients should be monitored for these events, especially when starting therapy or adjusting the dose.

Ivabradine is contraindicated in patients with severe sinus bradycardia (resting heart rate <50 bpm), acute decompensated heart failure, sick sinus syndrome, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.